Trial · NCT03782792
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 | Placebo | 0.056 | 95% Confidence Interval 0.010 to 0.258 | Proportion of participants | |
| Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 | Spesolimab 900 mg i.v SD | 0.543 | 95% Confidence Interval 0.382 to 0.695 | Proportion of participants | |
| Key Secondary: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Score of 0 or 1 at Week 1 | Placebo | 0.111 | 95% Confidence Interval 0.031 to 0.328 | Proportion of participants | |
| Key Secondary: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Score of 0 or 1 at Week 1 | Spesolimab 900 mg i.v SD | 0.429 | 95% Confidence Interval 0.280 to 0.591 | Proportion of participants | |
| Proportion of Patients With a Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI) 75 at Week 4 | Placebo | 0.111 | 95% Confidence Interval 0.031 to 0.328 | Proportion of participants | |
| Proportion of Patients With a Psoriasis Area and Severity Index for Generalized Pustular Psoriasis (GPPASI) 75 at Week 4 | Spesolimab 900 mg i.v SD | 0.457 | 95% Confidence Interval 0.305 to 0.618 | Proportion of participants | |
| Change From Baseline in Pain Visual Analog Scale (VAS) Score at Week 4 | Placebo | NA | Inter-Quartile Range NA to NA | Units on a scale | |
| Change From Baseline in Pain Visual Analog Scale (VAS) Score at Week 4 | Spesolimab 900 mg i.v SD | -22.45 | Inter-Quartile Range -70.41 to NA | Units on a scale | |
| Change From Baseline in Psoriasis Symptom Scale (PSS) Score at Week 4 | Placebo | NA | Inter-Quartile Range NA to NA | Units on a scale | |
| Change From Baseline in Psoriasis Symptom Scale (PSS) Score at Week 4 | Spesolimab 900 mg i.v SD | -2.0 | Inter-Quartile Range -9.0 to NA | Units on a scale | |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Week 4 | Placebo | NA | Inter-Quartile Range NA to NA | Units on a scale | |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score at Week 4 | Spesolimab 900 mg i.v SD | 3.00 | Inter-Quartile Range NA to 30.00 | Units on a scale | |
| Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Score of 0 or 1 at Week 4 | Placebo | 0.111 | 95% Confidence Interval 0.031 to 0.328 | Proportion of participants | |
| Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Score of 0 or 1 at Week 4 | Spesolimab 900 mg i.v SD | 0.486 | 95% Confidence Interval 0.330 to 0.644 | Proportion of participants | |
| Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Sub-score of 0 Indicating no Visible Pustules at Week 4 | Placebo | 0.111 | 95% Confidence Interval 0.031 to 0.328 | Proportion of participants | |
| Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Sub-score of 0 Indicating no Visible Pustules at Week 4 | Spesolimab 900 mg i.v SD | 0.514 | 95% Confidence Interval 0.356 to 0.670 | Proportion of participants | |
| Proportion of Patients With a Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 4 | Placebo | 0.111 | 95% Confidence Interval 0.031 to 0.328 | Proportion of participants | |
| Proportion of Patients With a Generalized Pustular Psoriasis Area and Severity Index (GPPASI) 50 at Week 4 | Spesolimab 900 mg i.v SD | 0.543 | 95% Confidence Interval 0.382 to 0.695 | Proportion of participants | |
| Percent Change in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) From Baseline at Week 4 | Placebo | NA | Inter-Quartile Range NA to NA | Percentage change | |
| Percent Change in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) From Baseline at Week 4 | Spesolimab 900 mg i.v SD | -60.50 | Inter-Quartile Range -88.37 to NA | Percentage change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03782792/results